TVGN Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

8.129

Open

7.510

VWAP

7.74

Vol

34.76K

Mkt Cap

31.40M

Low

7.315

Amount

269.18K

EV/EBITDA(TTM)

--

Total Shares

4.03M

EV

45.19M

EV/OCF(TTM)

--

P/S(TTM)

--

Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy company. The Company is harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs), to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the unmet needs of patient populations. Its first product candidate, TVGN 489, has developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic lingering symptoms of the disease. Its TVGN 601 is being developed for multiple sclerosis (MS), and its TVGN 930 is being developed for EBV-associated lymphomas.

Show More

Events Timeline

(ET)

2026-03-09

07:50:00

Tevogen Appoints Interim Leaders to Drive Growth Strategy

2026-03-06 (ET)

2026-03-06

15:50:00

Tevogen CEO Updates Strategic Acquisition Plans, Annual Revenue Over $50 Million

2026-03-06

10:20:00

Tevogen Bio Holdings Inc Trading Halted Due to Volatility

2026-03-05 (ET)

2026-03-05

19:50:00

Tevogen Bio Holdings Inc Trading Halted, News Pending

2026-03-05

15:00:00

Tevogen Signs Letter of Intent with Apozeal for Strategic Transaction

2026-03-04 (ET)

2026-03-04

08:10:00

Tevogen Approves 1-for-50 Reverse Stock Split

2026-02-27 (ET)

2026-02-27

14:30:00

Tevogen Signs Letter of Intent for Potential Transaction with Global CRO

2026-02-26 (ET)

2026-02-26

09:30:00

Tevogen Signs Letter of Intent to Evaluate Transaction with Sciometrix

News

Benzinga

BETA Technologies Reports Disappointing Q4 Results

stocktwits

03-06stocktwits

Tevogen CEO Actively Evaluating Acquisition Opportunities

Benzinga

Tevogen Bio Advances Generics Acquisition Strategy

Benzinga

Marvell Technology Surges After Strong Q4 Earnings Report

stocktwits

03-06stocktwits

Tevogen Considers Acquisition of Apozel Pharmaceuticals

Newsfilter

03-05Newsfilter

Tevogen Enters Letter of Intent with Apozeal for Strategic Acquisition

Valuation Metrics

The current forward P/E ratio for Tevogen Bio Holdings Inc (TVGN.O) is -1.80, compared to its 5-year average forward P/E of -0.93. For a more detailed relative valuation and DCF analysis to assess Tevogen Bio Holdings Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-0.93

Current PE

-1.80

Overvalued PE

0.81

Undervalued PE

-2.67

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

biotech industry stock under 5 dollars

Intellectia · 282 candidates

Industry: Biotechnology & Medical ResearchPrice: <= $5.00

Ticker

Name

Market Cap$

Applied Therapeutics Inc

14.63M

Theriva Biologics Inc

6.85M

IO Biotech Inc

14.94M

Adial Pharmaceuticals Inc

6.04M

GRI Bio Inc

2.26M

Propanc Biopharma Inc

3.62M

stovks to buy on wed from 20 to 40 cents

Intellectia · 81 candidates

Price: $0.20 - $0.40

Ticker

Name

Market Cap$

Sangamo Therapeutics Inc

127.97M

Incannex Healthcare Inc

123.43M

Hyperscale Data Inc

96.48M

Aurelion Inc

95.26M

Robo.ai Inc

89.22M

CleanCore Solutions Inc

79.36M

Whales Holding TVGN

Trading Trends

People Also Watch

Frequently Asked Questions

What is Tevogen Bio Holdings Inc (TVGN) stock price today?

The current price of TVGN is 7.79 USD — it has increased 0.52

What is Tevogen Bio Holdings Inc (TVGN)'s business?

Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy company. The Company is harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs), to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the unmet needs of patient populations. Its first product candidate, TVGN 489, has developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic lingering symptoms of the disease. Its TVGN 601 is being developed for multiple sclerosis (MS), and its TVGN 930 is being developed for EBV-associated lymphomas.

What is the price predicton of TVGN Stock?

Wall Street analysts forecast TVGN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for TVGN is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Tevogen Bio Holdings Inc (TVGN)'s revenue for the last quarter?

Tevogen Bio Holdings Inc revenue for the last quarter amounts to -5.73M USD, decreased -5.85

What is Tevogen Bio Holdings Inc (TVGN)'s earnings per share (EPS) for the last quarter?

Tevogen Bio Holdings Inc. EPS for the last quarter amounts to USD, decreased

How many employees does Tevogen Bio Holdings Inc (TVGN). have?

Tevogen Bio Holdings Inc (TVGN) has 18 emplpoyees as of March 11 2026.

What is Tevogen Bio Holdings Inc (TVGN) market cap?

Today TVGN has the market capitalization of 31.40M USD.